Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging

Abstract

A wide variety of neuroendocrine tumours express somatostatin receptors, and can be visualized by radiolabelled somatostatin analogue scintigraphy. To investigate the value of [111In]-octreotide scintigraphy (Octreoscan), 48 patients (37 with proven carcinoid, pancreatic endocrine and medullary carcinoma of thyroid tumours, 11 with neuroendocrine syndromes multiple endocrine neoplasia (MEN-I) and Zollinger-Ellison syndrome (ZES) were examined with 111In-DTPA-D-Phe1-octreotide. Scintigrams were obtained at 24 and 48 h, and the results were compared with CT and magnetic resonance imaging (MRI). Thirty-five of 48 patients had positive [111In]-octreotide scintigraphy (23/25 (92%) carcinoids, 8/9 (89%) PETs, 4/11 (36%) MEN-I & ZES). Of the 42 lesions located by conventional imaging techniques, 37 (88%) were also identified by Octreoscan. Unexpected lesions (40 sites), not detected by CT or MR imaging were found in 24/48 (50%) patients. [111In]-octreotide scintigraphy has a higher sensitivity for tumour detection, and is superior to MR imaging and CT scanning in the identification of previously unsuspected extraliver and lymph node metastases. It may also be helpful for the localization of clinically suspected tumours in patients with MEN-I and ZES.

Primary hepatic carcinoid: A case report and literature review

“…Findings using this application are encouraging, allowing the identification of the primary tumor in 84% of cases [14,15] . Primary carcinoid tumors and distant metastasis in patients affected by neuroendocrine tumors are better detected by otreoscan scintigraphy compared to the CT scan and the MRI [16] . The presence of somatostatin receptors within the tumoral cell is best suited for scintigraphy.…”

“…The presence of somatostatin receptors within the tumoral cell is best suited for scintigraphy. There are five receptor subtypes (SSTR 1-5) each having different functional properties and binding specificity for the target tissue [16] . Octreotide binds with high affinity to the somatostatin subtype 2 receptor (SSTR 2), which is widely expressed on the cell surface with neuroendocrine characteristics.…”

Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy

“…18 F-FDG PET may be helpful in the diagnosis of metastasis with high anaerobic glycolysis and low somatostatin receptor expression. As published earlier, MRI has been the most sensitive modality for detection of bone metastases in neuroendocrine tumor (32)(33)(34)(35) but is usually done to investigate regions of the body suspected of harboring bone metastases.…”

Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

“…Taken together CIT, including neck ultrasonography, CT, and MR of neck mediastinum, liver, and bone scintigraphy, is associated with a low detection rate in this setting since at least 50% of MTC metastatic lesions remain unidentified (Shulkin & Shapiro 1990, Shi et al 1998, Kebebew et al 2000, Leboulleux et al 2004.…”